Chinese phase 2 trial finds COVID-19 vaccine is safe and induces an immune response. A phase 2 randomized controlled trial of a recombinant adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine) was conducted in China in April 2020 and involved more than 500 people. The primary objective of the study was to evaluate the immune response and safety of the vaccine, and to determine the most suitable dose for a phase 3 trial. Phase 3 trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection. Source 9z.
Three-quarters of Wuhan patients hospitalized for COVID-19 still had symptoms 6 months later, Chinese study finds. Most patients who had been hospitalized with COVID-19 still suffered a variety of symptoms - including fatigue and sleep difficulties - six months after infection, a Chinese study has found. The study of more than 1,700 patients treated in the Chinese city of Wuhan, the original epicenter of the pandemic, shows 76% suffered at least. Source 7g.
Wuhan team delivers COVID-19 bombshell. Experts revealed it is “extremely unlikely” the virus came from a lab — and it may well have originated with a species other than bats. Source 8l.